Probabilities of acute and chronic GVHD, nonrelapse mortality, relapse, and OS by donor type
| . | Donor type . | . | |
|---|---|---|---|
| Outcome . | Haploidentical . | Unrelated . | P . |
| Myeloablative transplants | |||
| Grade 2-4 acute GVHD at day 90 | 16% (10-24) | 33% (30-35) | <.0001 |
| Grade 3-4 acute GVHD at day 90 | 7% (3-13) | 13% (11-15) | .02 |
| Chronic GVHD | |||
| At 12 mo | 28% (20-37) | 45% (42-47) | .0005 |
| At 36 mo | 30% (21-39) | 53% (50-56) | <.0001 |
| Nonrelapse mortality | |||
| At 12 mo | 12% (7-19) | 14% (12-16) | .56 |
| At 36 mo | 14% (8-22) | 20% (18-22) | .14 |
| Relapse | |||
| At 12 mo | 41% (33-50) | 32% (30-35) | .04 |
| At 36 mo | 44% (34-53) | 39% (37-42) | .37 |
| OS | |||
| At 12 mo | 65% (56-73) | 65% (63-68) | .98 |
| At 36 mo | 45% (36-54) | 50% (47-53) | .38 |
| Reduced intensity transplants | |||
| Grade 2-4 acute GVHD at day 90 | 19% (12-28) | 28% (25-31) | .05 |
| Grade 3-4 acute GVHD at day 90 | 2% (0-7) | 11% (8-13) | <.0001 |
| Chronic GVHD | |||
| At 12 mo | 27% (19-37) | 43% (40-47) | .001 |
| At 36 mo | 34% (24-44) | 52% (48-55) | .002 |
| Nonrelapse mortality | |||
| At 12 mo | 6% (2-12) | 16% (13-18) | .0001 |
| At 36 mo | 9% (4-16) | 23% (19-26) | .0001 |
| Relapse | |||
| At 12 mo | 43% (32-53) | 34% (31-38) | .12 |
| At 36 mo | 58% (46-68) | 42% (38-45) | .006 |
| OS | |||
| At 12 mo | 64% (53-73) | 60% (56-63) | .46 |
| At 36 mo | 46% (35-56) | 44% (40-47) | .71 |
| . | Donor type . | . | |
|---|---|---|---|
| Outcome . | Haploidentical . | Unrelated . | P . |
| Myeloablative transplants | |||
| Grade 2-4 acute GVHD at day 90 | 16% (10-24) | 33% (30-35) | <.0001 |
| Grade 3-4 acute GVHD at day 90 | 7% (3-13) | 13% (11-15) | .02 |
| Chronic GVHD | |||
| At 12 mo | 28% (20-37) | 45% (42-47) | .0005 |
| At 36 mo | 30% (21-39) | 53% (50-56) | <.0001 |
| Nonrelapse mortality | |||
| At 12 mo | 12% (7-19) | 14% (12-16) | .56 |
| At 36 mo | 14% (8-22) | 20% (18-22) | .14 |
| Relapse | |||
| At 12 mo | 41% (33-50) | 32% (30-35) | .04 |
| At 36 mo | 44% (34-53) | 39% (37-42) | .37 |
| OS | |||
| At 12 mo | 65% (56-73) | 65% (63-68) | .98 |
| At 36 mo | 45% (36-54) | 50% (47-53) | .38 |
| Reduced intensity transplants | |||
| Grade 2-4 acute GVHD at day 90 | 19% (12-28) | 28% (25-31) | .05 |
| Grade 3-4 acute GVHD at day 90 | 2% (0-7) | 11% (8-13) | <.0001 |
| Chronic GVHD | |||
| At 12 mo | 27% (19-37) | 43% (40-47) | .001 |
| At 36 mo | 34% (24-44) | 52% (48-55) | .002 |
| Nonrelapse mortality | |||
| At 12 mo | 6% (2-12) | 16% (13-18) | .0001 |
| At 36 mo | 9% (4-16) | 23% (19-26) | .0001 |
| Relapse | |||
| At 12 mo | 43% (32-53) | 34% (31-38) | .12 |
| At 36 mo | 58% (46-68) | 42% (38-45) | .006 |
| OS | |||
| At 12 mo | 64% (53-73) | 60% (56-63) | .46 |
| At 36 mo | 46% (35-56) | 44% (40-47) | .71 |